TSHA
Taysha Gene Therapies, Inc. (TSHA) Risks & Opportunities Analysis (2026)
Overall Score
Financial Strength
Very strong liquidity with a current ratio of 17.8x and cash ratio of 17.5x.
Low leverage with debt-to-equity of 0.14x and debt-to-assets of 0.12x.
Net current asset value remains positive at $378.3M.
Profitability
Margins remain deeply negative, with operating margin at -27.9% and net margin at -27.3%.
Returns are still poor, including ROE of -56.2% and ROIC of -34.5%.
Gross margin is high at 84.0%, but it is not yet translating into bottom-line profitability.
Valuation
Valuation remains highly stretched on sales, with price-to-sales at 375.0x and EV-to-sales at 302.1x.
Negative earnings and cash flow keep traditional earnings and FCF multiples difficult to interpret.
Price-to-book is 6.1x, which is elevated for a company still posting losses.
Cash Flow
Operating cash flow is negative, with OCF per share at -$0.36 and free cash flow per share at -$0.37.
Free cash flow and operating cash flow yields remain negative, indicating ongoing cash burn.
Capex is modest relative to operating cash flow, but the business is still not self-funding.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Taysha Gene Therapies, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

